1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends

Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Asia

  • 135 pages, published in January 2013
  • By BCC Research
  • Report Number: 1057716


Table of Contents



The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes and for devices and instruments used in the diagnosis and monitoring of diabetes. Special emphasis is given to major forces contributing to the vigorous growth of the diabetes market. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2017. These forecasts are based on epidemiological data and projections, as well as on information about R&D trends and differential market potential on a country-by-country basis. Health care policies, demographics, and the wider economic environment are also taken into account.


It is widely recognized that the prevalence of the most common type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 diabetes are also on the rise, although to a less spectacular degree. These trends are of great concern, not only to the individuals affected, but also to governments and providers of health care. Indeed, the economic consequences of diabetes are vast, involving not only the direct burden of managing the disease but also the common and often catastrophic complications such as cardiovascular disease, peripheral neuropathy, and blindness.

Prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and health care agencies. The already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and to the suppliers of devices needed for disease monitoring.

Among the information needs of companies in this field is an accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next five years, and the impact of drugs and technical developments now in the pipeline.


This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the diabetes market, discussed both in global terms and in terms of the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on merger and acquisition (M&A) activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.

A comprehensive refresher course on diabetes is provided as an appendix.


The dimensions of the surging diabetes epidemic can be witnessed in stark outline against previous smaller estimates only a few years back. Increased awareness of this “modern plague” has led naturally to improved and more frequent testing practices. This new awareness has also led to improved treatment compliance by patients. Added to these are the more expensive therapies and increased penetration of continuous glucose monitoring (CGM) approaches, which all combine to build a public health menace of accelerating proportions.

For the purpose of market analyses in this report, the global market is defined as 13 countries which together make up over 80% of the total diabetes universe. These countries are the U.S., Canada, Brazil, Mexico, China, India, Japan, Russia, Germany, France, Italy, Spain and the U.K.

Market figures are based on revenues at the manufacturer level and are projected at 2012-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories discussed include insulins and oral hypoglycemic agents, devices including blood glucose monitors and accessories, and software aids to self-management of diabetes by patients.


Primary research for this report included interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consisted of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources, critically assessed by BCC.


This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information with regard to market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background information on the marketplace in which they are operating.


Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from health care institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.


Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you get this report now


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Epiomic Epidemiology Series: Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • March 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 1 Diabetes Mellitus in 12 Major Markets Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the ...

Global Market Study on Diabetic Foot Ulcer Therapeutics: Neuro-Ischemic Ulcers Segment to Dominate the Global Market in Revenue Terms Through 2024

  • $ 4900
  • Industry report
  • March 2017
  • by Persistence Market Research

In a new publication titled “Diabetic Foot Ulcer Therapeutics Market: Global Industry Analysis and Forecast, 2016–2024,” the analysts at Persistence Market Research have targeted five key geographies ...

Global Diabetes Drugs Market Growth, Trends and Forecasts (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The diabetes drugs market, valued as a USD 20 billion market in 2010, is expected to grow at an exponential rate and become a USD 32 billion market by 2017, at a CAGR of about 7.5%. Diabetes, often referred ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.